What Is Amneal Pharmaceuticals, Inc. (AMRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Amneal Pharmaceuticals, Inc.'s intrinsic value is estimated at $10.28. Trading at its current price of $17.18, the valuation engine raises significant caution: 9 of 12 models flag downside risk, projecting an average implied return of -40.1%. The most optimistic model, First Chicago, places fair value at $33.77 (+96.5%), while Markov DDM — the most conservative — estimates $0.00 (-100.0%). This +196.5% gap reflects genuine analytical uncertainty about Amneal Pharmaceuticals, Inc.'s intrinsic worth.
What Do the Models Say About AMRX?
12 of 13 models are currently active for AMRX. Of these, 3 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates AMRX's intrinsic value at $1.69, implying -90.2% downside from the current price. See which stocks rank higher →
How Does AMRX Rank in Drug Manufacturers - Specialty & Generic?
Among 13 Drug Manufacturers - Specialty & Generic stocks, AMRX ranks #3 by Quality of Company score. CirclFi's QOC score of 8.0/10 evaluates 32 fundamental signals. A score of 8.0 indicates above-average quality.
The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to pharmaceutical industry businesses. For Amneal Pharmaceuticals, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is AMRX a Value Trap?
CirclFi's Value Trap algorithm assigns AMRX a score of 5/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Amneal Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Amneal Pharmaceuticals, Inc. scores 8.0 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +196.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AMRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AMRX's 12 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad